MMED
Premium GrowerMiniMed Group, Inc. · Healthcare · United States · $5.2B cap · $261.6M/day traded
$18.25 +5.1% · close 11 Nov · scored 11 Nov
Premium Grower: Strong business with the market behind it, priced at a premium.
As of 11 Nov 2026, the MoatMap Score for MiniMed Group, Inc. (MMED) is 59/100, ranked against 25,000+ stocks in 38 markets (Quality 53, Value 42, Momentum 60, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT MINIMED GROUP, INC.
Read
Minimed Group, Inc. is a healthcare company focused on the development and commercialization of medical products or services, likely within a specialized therapeutic area or medical device segment. The company aims to differentiate through innovation and targeted solutions that address specific patient needs. Its success hinges on clinical validation, regulatory approvals, and effective market penetration in a competitive healthcare landscape.
FINANCIAL SUMMARY (USD)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.2B | 2.5B | 2.7B | 3.1B | 11.4% | 3.2B | 3.6B | 3.9B | 12.3% |
| EPS | -0.34 | -0.40 | -0.76 | -1.30 | — | -1.53 | — | — | — |
| Shares | — | 280.8M | 280.8M | 280.8M | +0.0% | 281.3M | — | — | — |
| Debt | — | 8.0M | 11.0M | 145.0M | 325.7% | 59.0M | — | — | — |
| Equity | — | 3.4B | 3.3B | 3.6B | 2.3% | — | — | — | — |
| Op CF | -6.0M | 41.0M | 140.0M | -197.0M | 241.5% | -105.0M | — | — | — |
| Inv CF | -180.0M | -157.0M | -193.0M | -233.0M | — | — | — | — | — |
| Fin CF | 185.0M | 112.0M | 10.0M | 716.0M | — | — | — | — | — |
Not enough steady price history for a read yet.
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MMED are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| MMED | MiniMed Group, Inc.(you) | $5.2B | 59 |
| TFX | Teleflex Incorporated | $5.8B | 65 |
| ATRC | AtriCure, Inc. | $3.0B | 61 |
| WRBY | Warby Parker Inc. | $3.2B | 54 |
| ATR | AptarGroup, Inc. | $8.0B | 66 |
| ICUI | ICU Medical, Inc. | $4.2B | 72 |
| RGEN | Repligen Corporation | $11.2B | 53 |
| COO | The Cooper Companies, Inc. | $11.6B | 69 |
| XRAY | DENTSPLY SIRONA Inc. | $1.9B | 51 |
| SOLV | Solventum Corporation | $14.5B | 67 |
Peer medians: ROE -31.0% · P/E 25.9x · Gross margin 63.3%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.